The Bottle Neck in MS Drug Development

I would like to stress that there is no shortage in potential drugs for treating MS; this includes both the relapsing and progressive phases. The problem in my opinion are the costs associated with drug development, the lack of a tried-and-tested rapid phase 2 trial for assessing neuroprotective therapies and  the lack of focus on preventative strategies. The following is a figure demonstrating the current bottle-neck in MS drug development: